サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1320005

2型糖尿病治療薬市場：薬剤別、用途別、流通別-2023-2030年の世界予測

Type 2 Diabetes Drugs Market by Drug, Application, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
2型糖尿病治療薬市場：薬剤別、用途別、流通別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2型糖尿病治療薬の世界市場は、2023年にCAGR 8.74%で711億7,000万米ドル、2030年には1,285億5,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の2型糖尿病治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.2型糖尿病治療薬の世界市場規模および予測は？

2.予測期間中、世界の2型糖尿病治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.2型糖尿病治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.2型糖尿病治療薬の世界市場における競争戦略は？

5.2型糖尿病治療薬の世界市場における技術動向と規制の枠組みは？

6.2型糖尿病治療薬の世界市場における主要ベンダーの市場シェアは？

7.2型糖尿病治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界の糖尿病有病率の重要性
      • 不健康な食事と座りっぱなしのライフスタイルに伴う肥満人口の増加
      • 健康意識を高めるための政府の取り組みとプログラム
    • 抑制要因
      • ブランドの評判に影響を与える製品リコール
    • 機会
      • 製薬メーカーによる糖尿病治療薬の進歩
      • 研究開発とヘルスケアインフラ開発への投資が増加
    • 課題
      • 厳しい規制環境と時間のかかる承認プロセス
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 2型糖尿病治療薬市場薬物別

  • 注射剤
    • 一部として
    • エクセナチド
    • グラルギン
    • インスリン
    • レラグルチド
    • プラムリンチド
  • オーラル
    • α-グルコシダーゼ阻害剤
    • ビグアニデス
    • ジペプチジルペプチダーゼ-4阻害剤
    • グルカゴン様ペプチド
    • 受容体アゴニスト
    • 分泌促進物質
    • ナトリウムグルコース共輸送2阻害剤
    • スルホニル尿素
    • チアゾリジンジオン

第7章 2型糖尿病治療薬市場：用途別

  • 心臓血管の安全性
  • 血糖コントロール
  • 低血糖の回避

第8章 2型糖尿病治療薬市場配信別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカの2型糖尿病治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の2型糖尿病治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの2型糖尿病治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. TYPE 2 DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. TYPE 2 DIABETES DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
  • FIGURE 5. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 7. TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. TYPE 2 DIABETES DRUGS MARKET DYNAMICS
  • FIGURE 9. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 5. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 6. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. TYPE 2 DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 14. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DIPEPTIDYL PEPTIDASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. TYPE 2 DIABETES DRUGS MARKET SIZE, BY RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORT 2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. TYPE 2 DIABETES DRUGS MARKET SIZE, BY CARDIOVASCULAR SAFETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. TYPE 2 DIABETES DRUGS MARKET SIZE, BY HYPOGLYCEMIA AVOIDANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. TYPE 2 DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. TYPE 2 DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. TYPE 2 DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLES, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 241. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 242. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 243. TYPE 2 DIABETES DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-7162E4C3E9E3

The Global Type 2 Diabetes Drugs Market is forecasted to grow significantly, with a projected USD 71.17 billion in 2023 at a CAGR of 8.74% and expected to reach a staggering USD 128.55 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Type 2 Diabetes Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Type 2 Diabetes Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Injectables and Oral. The Injectables is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral is further studied across Alpha-Glucosidase Inhibitors, Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Glucagon-Like Peptide, Receptor Agonists, Secretagogues, Sodium Glucose Cotransport 2 Inhibitors, Sulfonylureas, and Thiazolidinediones. The Injectables is projected to witness significant market share during forecast period.

Based on Application, market is studied across Cardiovascular Safety, Glycemic Control, and Hypoglycemia Avoidance. The Cardiovascular Safety is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Type 2 Diabetes Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Type 2 Diabetes Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 2 Diabetes Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 2 Diabetes Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Type 2 Diabetes Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Type 2 Diabetes Drugs Market?

6. What is the market share of the leading vendors in the Global Type 2 Diabetes Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Type 2 Diabetes Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Type 2 Diabetes Drugs Market, by Drug, 2022 vs 2030
  • 4.3. Type 2 Diabetes Drugs Market, by Application, 2022 vs 2030
  • 4.4. Type 2 Diabetes Drugs Market, by Distribution, 2022 vs 2030
  • 4.5. Type 2 Diabetes Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significance of diabetic prevalence globally
      • 5.1.1.2. Rise in obesity population coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.3. Government initiatives and programs to create health awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Products recall affecting brand reputation
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
      • 5.1.3.2. Rising investment in R&D and healthcare infrastructure development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and time-consuming approval process
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Type 2 Diabetes Drugs Market, by Drug

  • 6.1. Introduction
  • 6.2. Injectables
    • 6.2.1. Aspart
    • 6.2.2. Exenatide
    • 6.2.3. Glargine
    • 6.2.4. Insulin
    • 6.2.5. Leraglutide
    • 6.2.6. Pramlintide
  • 6.3. Oral
    • 6.3.1. Alpha-Glucosidase Inhibitors
    • 6.3.2. Biguanides
    • 6.3.3. Dipeptidyl Peptidase-4 Inhibitors
    • 6.3.4. Glucagon-Like Peptide
    • 6.3.5. Receptor Agonists
    • 6.3.6. Secretagogues
    • 6.3.7. Sodium Glucose Cotransport 2 Inhibitors
    • 6.3.8. Sulfonylureas
    • 6.3.9. Thiazolidinediones

7. Type 2 Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Safety
  • 7.3. Glycemic Control
  • 7.4. Hypoglycemia Avoidance

8. Type 2 Diabetes Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Type 2 Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Type 2 Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Type 2 Diabetes Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing